肝细胞癌患者接受90Y经动脉放射性栓塞治疗后,18F-FDG PET/CT的总病变糖酵解是比90Y PET/CT的肿瘤剂量更好的预后因素
本研究回顾性纳入47例接受90Y经动脉放射性栓塞(TARE)的肝细胞癌(HCC)患者,评估治疗前18F-FDG PET/CT代谢参数与治疗后90Y PET/CT肿瘤剂量(TD)对总生存(OS)的预后价值。多因素分析显示BCLC C期和高TLG是OS的独立预后因素;低TLG组1年OS率为72.9%,高TLG组为33.3%。90Y PET/CT的TD与90Y微球给药剂量不相关,但与治疗前TLG负相关。
要点
- 治疗前18F-FDG PET/CT的TLG是HCC患者90Y TARE后OS的独立预后因素。
- 低TLG组1年OS率为72.9%,高TLG组为33.3%(P<0.05)。
- 90Y PET/CT的TD与微球给药剂量不相关,与治疗前TLG负相关。
核心结论
- 治疗前18F-FDG PET/CT的TLG是比90Y PET/CT的TD更好的预后因素,用于预测接受90Y TARE的HCC患者OS。
研究设计与样本
- 回顾性纳入2013年1月至2018年10月间接受90Y TARE治疗的47例HCC患者,治疗前行18F-FDG PET/CT测量TLR、MTV和TLG,治疗后行90Y PET/CT体素剂量学测量TD。
主要发现
- 中位年龄57岁,男性37例(78.7%);随访期间25例(53.2%)死亡。
- 单因素分析中,BCLC C期、Child-Pugh评分、90Y PET/CT的TD、TLR、MTV和TLG均为影响OS的显著预后因素(P<0.05)。
- 多因素分析中,BCLC C期和高TLG是OS的独立预后因素(P<0.05)。
- 低TLG组1年OS率为72.9%,高TLG组为33.3%(P<0.05)。
- 90Y PET/CT的TD与90Y标记微球给药剂量不相关,但与治疗前18F-FDG PET/CT的TLG负相关(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate the prognostic value of metabolic parameters on 18F-FDG PET/CT and tumor dose (TD) on posttreatment 90Y PET/CT in patients with hepatocellular carcinoma (HCC) who underwent 90Y transarterial radioembolization (TARE). PATIENTS AND METHODS: Forty-seven HCC patients treated with 90Y TARE were retrospectively enrolled between January 2013 and October 2018. 18F-FDG PET/CT was performed before treatment. Maximum tumor SUV-to-mean normal liver SUV ratio (TLR), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured for each patient. Voxel dosimetry was performed on 90Y PET/CT images to measure TD. The prognostic significance of metabolic parameters on 18F-FDG PET/CT, TD on 90Y PET/CT, and clinical factors for overall survival (OS) was evaluated. In addition, TD on 90Y PET/CT was analyzed in relation to the administered dose of 90Y-labeled microspheres and metabolic parameters on 18F-FDG PET/CT. RESULTS: The median patient age was 57 years, and 37 patients (78.7%) were men. During the follow-up period, 25 patients (53.2%) died. In univariable analysis, Barcelona Clinic Liver Cancer stage C, Child-Pugh score, TD on 90Y PET/CT, TLR, MTV, and TLG were significant prognostic factors affecting OS (P < 0.05). In multivariable analysis, Barcelona Clinic Liver Cancer stage C and high TLG on 18F-FDG PET/CT were independent prognostic factors for OS (P < 0.05). The 1-year OS rates were 72.9% in patients with low TLG and 33.3% in patients with high TLG (P < 0.05). We also found that TD on 90Y PET/CT was not correlated with the administered dose of 90Y-labeled microspheres, but negatively correlated with TLG on pretreatment 18F-FDG PET/CT (P < 0.05). CONCLUSIONS: TLG, a parameter incorporating both the degree of 18F-FDG uptake and amount of metabolically active tumor volume on pretreatment 18F-FDG PET/CT, is a better prognostic factor than TD on 90Y PET/CT for predicting OS in HCC patients treated with 90Y TARE.
引用
- Hwang SH, Hong HS, Kim D, et al. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization. Clin Nucl Med. 2022. PMID: 35384891. doi:10.1097/RLU.0000000000004128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。